Wolverine Trading, LLC Halozyme Therapeutics, Inc. Call Options Transaction History

Wolverine Trading, LLC

$93.9 Billion
Q3 2024

Call Options

24 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$51.3 - $64.42 $200,070 - $251,238	3,900 Added 66.1%	9,800 $560,000
Q2 2024 Aug 14, 2024	SELL	$37.81 - $52.4 $37,810 - $52,400	-1,000 Reduced 14.49%	5,900 $308,000
Q1 2024 May 15, 2024	SELL	$33.68 - $41.95 $47,152 - $58,730	-1,400 Reduced 16.87%	6,900 $280,000
Q4 2023 Feb 14, 2024	SELL	$33.32 - $42.1 $369,852 - $467,310	-11,100 Reduced 57.22%	8,300 $306,000
Q3 2023 Nov 15, 2023	BUY	$36.46 - $44.03 $707,324 - $854,182	19,400 New	19,400 $741,000
Q1 2023 May 15, 2023	BUY	$32.86 - $55.7 $253,022 - $428,890	7,700 New	7,700 $287,000
Q2 2022 Aug 15, 2022	BUY	$37.35 - $48.3 $18,675 - $24,150	500 Added 7.25%	7,400 $335,000
Q1 2022 May 16, 2022	SELL	$31.97 - $41.06 $79,925 - $102,650	-2,500 Reduced 26.6%	6,900 $278,000
Q4 2021 Feb 14, 2022	SELL	$31.82 - $40.75 $270,470 - $346,375	-8,500 Reduced 47.49%	9,400 $379,000
Q3 2021 Nov 12, 2021	BUY	$38.47 - $46.42 $465,487 - $561,682	12,100 Added 208.62%	17,900 $710,000
Q2 2021 Aug 06, 2021	SELL	$38.84 - $51.31 $155,360 - $205,240	-4,000 Reduced 40.82%	5,800 $265,000
Q4 2020 Feb 12, 2021	SELL	$25.81 - $43.62 $77,430 - $130,859	-3,000 Reduced 23.44%	9,800 $417,000
Q3 2020 Nov 13, 2020	BUY	$25.74 - $29.63 $64,349 - $74,075	2,500 Added 24.27%	12,800 $339,000
Q2 2020 Aug 13, 2020	SELL	$16.25 - $26.81 $105,625 - $174,265	-6,500 Reduced 38.69%	10,300 $266,000
Q1 2020 May 11, 2020	SELL	$13.9 - $21.83 $287,730 - $451,880	-20,700 Reduced 55.2%	16,800 $305,000
Q4 2019 Feb 12, 2020	BUY	$14.93 - $19.53 $88,087 - $115,227	5,900 Added 18.67%	37,500 $669,000
Q3 2019 Nov 14, 2019	BUY	$15.2 - $17.69 $115,520 - $134,444	7,600 Added 31.67%	31,600 $480,000
Q2 2019 Aug 20, 2019	BUY	$14.75 - $17.26 $70,800 - $82,848	4,800 Added 25.0%	24,000 $412,000
Q1 2019 May 15, 2019	SELL	$13.94 - $17.58 $337,348 - $425,435	-24,200 Reduced 55.76%	19,200 $309,000
Q4 2018 Feb 14, 2019	BUY	$13.33 - $18.66 $75,981 - $106,362	5,700 Added 15.12%	43,400 $620,000
Q3 2018 Nov 14, 2018	SELL	$16.68 - $18.41 $850,680 - $938,910	-51,000 Reduced 57.5%	37,700 $685,000
Q1 2018 May 15, 2018	SELL	$17.06 - $21.2 $1.21 Million - $1.5 Million	-70,700 Reduced 44.35%	88,700 $1.74 Million
Q4 2017 Feb 14, 2018	BUY	$16.75 - $20.8 $475,700 - $590,720	28,400 Added 21.68%	159,400 $3.23 Million
Q3 2017 Nov 15, 2017	BUY	$11.76 - $17.4 $1.54 Million - $2.28 Million	131,000	131,000 $2.28 Million

Others Institutions Holding HALO

# of Institutions

542

Shares Held

125M

Call Options Held

294K

Put Options Held

180K

Black Rock Inc. New York, NY

17.6M
Shares

$930 Million
0.02% of portfolio
Vanguard Group Inc Valley Forge, PA

12.9M
Shares

$681 Million
0.01% of portfolio
State Street Corp Boston, MA

6.63M
Shares

$350 Million
0.02% of portfolio
Snyder Capital Management L P San Francisco, CA

4.06M
Shares

$215 Million
5.07% of portfolio
Alliancebernstein L.P. New York, NY

3.41M
Shares

$180 Million
0.07% of portfolio

View Full List

About HALOZYME THERAPEUTICS, INC.

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $7.35B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

More about HALO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wolverine Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wolverine Trading, LLC with notifications on news.

Account